CARB-X is awarding BioVersys, a pharmaceutical company headquartered in Basel, Switzerland, up to US$4.35 million in non-dilutive funding, to develop a new class of…
CARB-X is awarding Swiss listed company Basilea Pharmaceutica International up to US $2.7m to develop a novel class of antibiotics to treat Gram-negative bacterial infections. The…
Sandoz, a Novartis division, has announced plans to invest €150m and further strengthen its European antibiotics manufacturing network by further expanding production capabilities in…
Up to $4.1 million in non-dilutive funding are being awarded by CARB-X to UK-based Summit Therapeutics. The capital is provided for the development of first-in-class antibiotics against…
BARDA is seeking proposals for a new Antibacterial Accelerator which is funded for the next ten years. It will set upon the results delivered…
End of April the General Assembly High-Level Interactive Dialogue on Tackling AMR took place as a virtual event. To raise global attention, a Call…
US pharma company Pfizer acquired US-based biotech company Amplyx Pharmaceuticals for an undisclosed sum. The deal provides Pfizer with a pipeline led by phase…
CARB-X is awarding GenomeKey (Genomics Labs Ltd.) in Bristol, UK, up to $3.0 million in non-dilutive funding to develop an innovative rapid diagnostic for…
US-based X-Biotix Therapeutics, focused on antibiotic compounds targeting multi-drug-resistant Gram-negative pathogens, will suspend its current antibacterial research efforts. The company will instead focus on…
